

AMENDMENTS TO THE SPECIFICATION

Please replace the previously amended paragraph bridging pages 8 and 9 with the following amended paragraph:

Technology has been developed previously to produce highly specific T cell receptors (TCR) which recognize particular antigen. For example, the pending U. S. patent publication US 2007/0116718A1 and USPN:6,534,633, incorporated herein by reference; and International publications WO 98/39482 and WO 00/23087, and references discussed therein disclose methods of preparing and using specific TCRs. Additionally, particular specific TCRs have been produced by recombinant methods as soluble, single-chain TCRs (scTCR). Methods for production and use of scTCRs have been disclosed and are described in International application WO 99/18129, which is incorporated herein by reference. WO 99/18129 discloses scTCR proteins include covalently linked TCR V α and V β chain fused to an immunoglobulin light chain constant region (ie. Ig-C₁) or a suitable Ig-C₁ fragment. WO 99/18129 discloses that in another aspect, the scTCR is provided without a fused Ig-C₁ chain or fragment. Such TCRs and scTCRs can be altered so as to create fusions or conjugates to render the resulting TCRs and scTCRs useful as therapeutics. The TCR complexes of the invention can be generated by genetically fusing the recombinantly produced TCR or scTCR coding region to genes encoding biologically active proteins to produce TCR fusion complexes. Alternatively, a TCR or scTCRs can also be chemically conjugated with biologically active molecules to produce TCR conjugate complexes.